Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CC is a long term treatment for 12 weeks compared to 5- 15 day COVID acute hospitalized treatment.
Primary endpoint is 50% reduction of cough vs COVID WHO scale.
...GLTA...
4/2022 article. PF/IPF/CC?
"
This review provides an overview of pulmonary fibrosis resulting from COVID-19 infection, addressing the possible ongoing treatments to prevent early mortality and prolong the survival of these patients."
https://www.cureus.com/articles/87859-post-covid-19-pulmonary-fibrosis
$1M+ now and $4M+ (IF) to keep 'going',,, toward the goals AGN is pursuing for us the speculative shareholders...GLTA...
https://finance.yahoo.com/news/algernon-pharmaceuticals-announces-closing-public-151400077.html
A bad choice of hard to prove endpoints. No Stelar results/data recorded during the crazy scrambles at the foreign hospitals. Everyone was getting 'Remdeathisnear' to confound some data results. *
AGN should Never had a 40 mg arm.!.
Investors and CSO/CEO were aiming for a home run when baserunners were what was needed then. A simple treatment, Not "the Cure" BS...IMO...
Some good data still and the IL-6 stuff too.
"Feedback from the FDA" and a pass at the DSMB, but they never applied for the Phase 3. Fair point.
https://ir.algernonpharmaceuticals.com/news-events/press-releases/detail/53/algernon-pharmaceuticals-receives-green-light-from-dsmb-to
Continued supporting data from the CC/IPF study for the use of Ifenprodil in chronic lung diseases seems probable.
IMO, do the $2M to keep rolling. ASAP. Prepare the next stepss ..GLTA...
*{Gilead (Wuhan V.I.-Bat Soup) Rem} bought up All the hospital beds to use for Rem CTs that eventually also showed no real results...IMO...
https://ir.algernonpharmaceuticals.com/news-events/press-releases/detail/35/algernon-pharmaceuticals-announces-topline-data-from-its
<>
The Company’s decision was based on several factors including the overall findings of the Phase 2b COVID-19 study final data set, the global rate of vaccinations to date, other COVID-19 drug treatment programs under development, and the projected trial size, costs and timelines needed to successfully complete a Phase 3 trial. Feedback recently received from the U.S. Food and Drug Administration regarding the Company’s end of Phase 2 meeting request was also informative.
https://ir.algernonpharmaceuticals.com/news-events/press-releases/detail/25/algernon-pharmaceuticals-announces-it-will-not-advance
Ifenprodil was approved to move to a Phase 3 COVID related trial. The COVID pandemic was wanning and vaccines from BP were being pushed. So not pursued.
Ifenprodil had specific positive effects, Data from the CC/IPF study may be related. BFD, IMO.
AGN/NASH is in Australia, so was the study.
I have seen a DMT trial for determining minimum dose levels for psychedelic results already done in the UK. We are all waiting for some news from there. BFD, IMO...
These two seem to be the main focus NOW...
...GLTA...
.
Simple math. You are apparently holding your shares expecting a significant PPS raise to sell in to, provided by the possible success of at least one of the three (4) paths that AGN is attempting. Tough projects with possible good rewards.
Speculating like all the rest of us shareholders. Everyone does DD. All know the Good and Bad possibilities and have made the Risk to Reward assessment as defined by their personal opinions. You're holding. So am I.
...GLTA...
A 'measly $9M' is twice the MC. I dont know if there is another LS% or other person/group that CAN make those kinds of speculative investments. We're waiting impatiently for confirmations and acceptance from the UKMHRA or FDA. Duh.
The COVID chase results were 'not stellar' enough to do a Phase 3 directed at the flagging COVID epidemic. NONE of the other COVID treatments were either. BP can $pread their true lies. Remdesivir, PFE-MRNA (C-19 specific) vaccines.?. AGN does not have a Dr Fakee to twist spins, only a fairly honest CSO describing 'trends' in a herd of BP$ B$.
Unconfident and opinionated claims of incompetence? GLWT in the mirror. Future or past, crystal balls or Hind sighting others. Talk to the mirror again, IMHFO....
Trading advice may be heeded. Mitigating some losses due to 'not stellar' COVID results seemed obvious as AGN sought complementary paths that may use the Data gleaned from existing work and new paths with possibilities. NO Guarantees from ANY company EVER that I have seen..
Buy-Hold-Sell.
...GLTA...
So, approvals from the UK MHRA for Stroke research with micro dosed DMT wont attract serious interest.?. A real clinical application seems supported and we can assume there was some work needed.
An adjunct use of Ifenprodil with chemo for SCLC and cancer tumors may also be 'chased'. AGN licensed the IP.
One trick pony? Speculative investment and always has been, IMO.
The endpoints for the CC/IPF study will at least enable something CC. Maybe in Australia as AGN/NASH have THAT door as a solid backstay.
Most of us have been here through a lot chasing Breath and COVID. We know the past. There were obvious chances and risks.
I am speculating on the possible positive future.
These are ALL possibly big deals, IMO. A sustainable pipeline?
The current cards could be played quick as Shell implies some might. (imo). Long ago I posted to push the BTH run with small buys ( at least) to enable a BLO type run.
With some Positive Results and thoughtful actions AGN may move quick AND sustainably. .. (insert Sly + Family Stone @ Woodstock).
...GLTA...
...
Nasdag/US F1 on 5-9 was for 45 days, ending 6-24?
CSE only for this F1?
Different requirements, registration and costs?
Until AGN gets something from UK MHRA about the Stroke initiative or from FDA for CC or oncology it's hard work and they need funds to pursue this all.?.
It seems that re-writing parts of the applications and/or specifics about the Trials are still in work.
Oncology and Stroke are tough areas. IPF/CC may be first. I had hope for quick UK Trial support and strong interest in Australia to continue the IPF/CC work. I hope applications to cancer foundation were made.
I'm not selling at these tree shakes at this point, stubborn and holding to see all the cards. < .003% of OS = -20+%?.........
...GLTA...
According to the latest F-1/A Registration Statement filed on 2022-05-09 with US SEC:
"We have applied to have our Common Shares listed on the Nasdaq Capital Market under the symbol "AGNP" and recently received approval to list our Common Shares on Nasdaq Capital Market."
Yes, hard to find. I Hope for Positive news on Stroke, IPF/CC Data and Clinical Trials and Oncology for SCLC and Pancreatic/tumors. Certainly ALL need the Best efforts from our company teams to make a successful IPO.
In this company review of actions and challenges, I found this Bth 'device' reference? A reason for the NASH deal? Ending UF licensing.
"In regards to its medical device, the Company has certain direct competition from Menssana Research Inc., which is based in New Jersey, U.S. and Owlstone Nanotech Inc., which is based in the United Kingdom.
These companies have the financial ability to compete directly with the Company"
Agn IP now at Blo as some say? Cant find that. Any residual value?
...GLTA...
Test your knowledge of psychedelic drugs... From Charles River Labs Finland, Eureka blog... Hmmm...GLTA...
https://www.criver.com/eureka
"The potential resources are greater, and the graphite content of the Lac Guéret ore is five times higher than that of Nouveau Monde Graphite's Matawinie mine in Saint-Michel-des-Saints"
And in China?
"Graphite is often a very underrepresented critical mineral in the lithium-ion battery," Miller said. "Especially, not enough attention is paid to the potential for supply deficit and to the potential for the graphite market itself to become structurally affected by demand from electric vehicles."
Graphite flake prices in China stood at $760 per ton in early February, up by 11.8% from January and up by 38.2% from a year ago, according to Rystad Energy's monthly price index.
>
Syrah's Vidalia plant, which would process graphite mined in Mozambique, would be the first US-based facility producing natural graphite anodes.
Canadian developer Nouveau Monde Graphite is also planning to set up a battery anode facility near Montreal in Canada.
https://www.dw.com/en/chinese-graphite-dominance-threatens-electric-car-ambitions/a-60888876
Yes, he said $.20 valuation after top line data showed no 'magic wand' for COVID. Neither did Remdesivir, but they sure glommed most Clinical Trials pushing their drug and sold millions of doses around the world with low success compared to their Trial's primary and secondary endpoints and safety issues, IMO. AGN couldnt afford a Phase 3 WITHOUT a 'magic wand', IMO. COVID had vaccines being pushed. AGN needed a new path...IMHFO-.*
( A.U recs on Gld? LOL)
anyway
I took his advice at the time and 'joined the crowd' with many of my long held shares in that obvious rec. Pretty easy call. Bought the pre R/S sale as I feel different about the future of AGN's prospects than you. Maybe I can even buy 100 shares and move the pps 5% like today.
...GLTA...
Rem = Gilead / Wuhan Virologic Institute / coronavirus and batshit soup...
Hmmm, been closed for 2 years...GLTA...
https://www.reuters.com/world/asia-pacific/australia-fully-reopen-borders-vaccinated-travellers-feb-21-2022-02-07/
https://www.australianclinicaltrials.gov.au/why-conduct-clinical-trial-australia
https://www.australianclinicaltrials.gov.au/
https://www.australia.com/en-us/travel-alerts/coronavirus.html
https://www.worldometers.info/coronavirus/
Algernon Pharmaceuticals has reported that NP-120 (Ifenprodil) statistical significantly lowered interleukin 6 (IL-6) in its Phase IIb/III trial to treat Covid-19.
The change in IL-6 levels was one of the biomarkers assessed in this trial.
In a statement, Algernon said: “In the measurement from baseline to day five, IL-6 was reduced in the 20mg treatment arm by 267ng/L, versus 7ng/L in the standard of care arm.”
The results from the Covid-19 study could inform the ongoing Phase II trial of Ifenprodil to treat idiopathic pulmonary fibrosis (IPF) and chronic cough, the company noted.
Encoded by the IL-6 gene, IL-6 functions as a pro-inflammatory cytokine and an anti-inflammatory myokine.
By causing chronic inflammation, IL-6 can lead to fibrosis. In patients with IPF, IL-6 is observed to be higher and its inhibition was found to reduce pulmonary fibrosis in a mouse model.
Earlier this week, Algernon had completed 50% enrolment in the Phase II trial of Ifenprodil for IPF and chronic cough. Changes in IL-6, as well as other fibrosis markers, including C-reactive protein and collagen pro-peptides, will be evaluated in this study.
https://www.pharmaceutical-technology.com/news/algernon-ifenprodil-covid-trial/
We know that the company's Ifenprodil focus had modified and that the company"s efforts were mainly COVID in 2020-2021. They got it done under adverse issues. A Phase 3 was not pursued due to costs and vaccinations. The company PR'ed the strong ILK-6 data and obviously has that Trial's data as support for future applications.
IPF/CC was delayed due to COVID but many here hope that Data may finally substantiate Ifenprodil's value for these Lung diseases and to support other Trial applications.
2021 brought licensing of Sub-hallucinogenic micro dose DMT research to pursue along with world class advisors. UK-MHRA applications in 2-2022.
AGN also found and licensed the Stroke research from Dr North (Topotecan) about the SCLC/Pancreatic tumor stuff. Very encouraging, IMO. (personal interest in cancer)
Not bad for a speculative investment, IMO. Buy -Hold - Sell...
I hope you're right about the FDA and implied UK-MHRA approvals of Clinical Trials. I've seen one with DMT and smoking.?.
BUTT... Of course it's not that easy. JMHFO...GLTA...
There was a positive response from the FDA for the Topotecan/Ifenprodil combination treatments of SCLC back in Nov 2021.
News due here for AGN's Nasdaq IPO.
More significantly, combination treatments of xenografts in mice with ifenprodil and the chemotherapeutic agent topotecan produced clear additive effects that completely stopped tumor growth. Moreover, the ifenprodil and topotecan combination showed excellent supra-addition or synergy of inhibition for tumors ≤300 mm in size (P=4.7E-4). Combination treatment of memantine with topotecan also showed clear addition but, unlike ifenprodil, no synergy for the doses chosen.
Conclusion: Since topotecan is a drug of choice for treatment of rSCLC, our findings suggest that combining this agent with NMDA receptor blockade using the GluN2B antagonist, ifenprodil, will significantly improve patient outcomes.
https://www.dovepress.com/small-cell-lung-cancer-growth-inhibition-synergism-between-nmda-recept-peer-reviewed-fulltext-article-CPAA
https://www.dovepress.com/small-cell-lung-cancer-growth-inhibition-synergism-between-nmda-recept-peer-reviewed-fulltext-article-CPAA
Sure I/we hope for our fair share, 50% of our company. Taking us to the Nasdaq with a true medical play for DMT, an IPF/CC interim data success with continuity to a next Phase and hooking a big fish for non dilutive financing for the SCLC / pancreatic cancer tumor treatment make a possible NASDAQ Golden Ticket.
The Big Risks we have all supported should have Big Rewards. Could happen with successes.
My dreams are not an investment strategy yet, but like others I have bought and drank the kool-aid. Too late to puke it up now, so I will ride out the trip. A 'long strange trip it's been', too. Almost intolerable waiting. Unimagined circumstances.
CEO CM and the BoD can set the IPO to Reward Long time investors AND employees AND the future PP investors. Of course, it all depends on the level of successes with the current projects, IMO.
Working from their home offices implies needed strict expense controls. They SHOULD be jumping thru all kinds of hoops and wearing out their phones and computers. GOOD. I'm sure they want strong reasons to Reward themselves too. An IPO to the Nasdaq is The Big opportunity for us ALL.
Probably a good time to write CM with opinions, IMO.!.!.!...GLTA...
OAN, Bad form to tantrum. Accept the outcome of the cards and how one played them. JAFO...
Luckly we all have a concerned citizen repeatably posting the all doom scenarios for ages to help suppress the pps while complaining about loss of it's moneyshot and blaming other's for a 4 year+ hold thru the company's struggles to produce a winning ticket. Very few have traded to profits here so far, some have mitigated the damage though. Speculative investments are that way. Duh.
MY Nasdaq 10M OS concept includes a 3 for 1 to longs. Duh...
I wrote and complained about the value loss of long time shareholders and suggested the possibility of rewarding longs IF successes warrant it in the IPO. A higher MC could happen before the IPO, enabling 'stuff'.
Bad news and we all lose. Good news and long time shareholders should win too, not just the newest PP holders. IMO.
ALL shareholders can pen emails with their expectations or write floundering epitaphs and excessive hind sighted whiney posts on message boards. Buy or Hold or Sell
BTW, name a stock where an IPO does not have bonuses/stock for management, etc.
...GLTA...
Was there more to the discussion or a response? When was this all written? Why post it here? ...
.I think that the announcement of an approved Phase 1 Clinical Trial by the UK-MHRA for Stroke using micro-dosed DMT, ALONG with other news that is due, will make a difference in PPS and allow for a larger MC to do stuff as the IPO unfolds.
All proportionate to the levels of success...IMO.
Maybe even reward long term shareholders.?. Bonuses for sure.
(3x1.7M) = 5.1M +5.6M (+) = about 11M OS?
Just another message board poster's opinion.
Was there more to the discussion or a response? When was this all this written? Why post it here? ...
.I think that the announcement of an approved Phase 1 Clinical Trial by the UK-MHRA for Stroke using micro-dosed DMT, ALONG with other news that is due, will make a difference in PPS and allow for a larger MC to do stuff as the IPO unfolds.
All proportionate to the levels of success...IMO.
Maybe even reward long term shareholders.?. Bonuses for sure.
(3x1.7M) = 5.1M +5.6M (+) = about 11M OS?
Just another message board poster's opinion.
Sad the microdose DMT UK MHRA clinical trial application approvals have taken so long. The pps reflects the delay as does the add-on to the initial prospectus. With these delays in getting approvals and the probable extra documentations needed, AGNPF is still spending to get it done. Sucks to be a long time supporter/shareholder right now. Double down or fold.?.
There is this nugget of 'newspeak' I had not seen before implying NASDAQ listing approval....
" We have applied to have our Common Shares listed on the Nasdaq Capital Market under the symbol "AGNP" and recently received approval to list our Common Shares on Nasdaq Capital Market. The successful listing of our Common Shares and Warrants on the Nasdaq Capital Market is a condition of this offering. We do not intend to apply for listing of the Pre-Funded Warrants on the Nasdaq Capital Market."
...GLTA...
The criminal Dr JJ could have joined RLF with their ACER sub and the Nrx drugs to become a Real pharma. But NO, personal greed, incompetent CT design and implementation by this criminal has delayed and then ruined most possibilities.
Sorry for the venting to all still invested. I lost on RLF too. Worst slime ball POS I've ever heard of. GEM must be so happy, they've been filling his pockets for years before Avitadil which is better and safer than Paxlovid Criminal incompetence on so many levels, IMO.
...GLTA...elsewhere...
Were the Ifenprodil COVID Clinical Trial results BETTER than the Pfizer pill Paxlovid? Safety?
Big Pharma monie$.?. Does this infer strong results for the Ifenprodil IPF/CC study?
...GLTA...
https://www.investopedia.com/pfizer-covid-treatment-pill-falls-short-5271094
https://www.deseret.com/coronavirus/2021/12/27/22855500/pfizer-covid-pill-covid-19-symptoms-risky-side-effects?msclkid=b03957f8cd5811ec92bafc8932c10d79
Looks like they have made their target dates. Just confirming the completion and actual top line data date.?.
Primary Completion: May 2022 [Anticipated]
Study Completion: June 2022 [Anticipated]
https://clinicaltrials.gov/ct2/history/NCT04318704?A=1&B=9&C=Side-by-Side#StudyPageTop
Australia and NZ have had serious COVID issues even after closing their countries initially in 2020. For a while Australia was one of the lowest infected countries. Now it is one of the worst.
Sad for all Ausies and that it affected our CT too, making it take this long.
Sure hope the wait proves worthwhile.
Australia Total 6,130,748 New cases +54,868 hospitalized 7,423
https://www.worldometers.info/coronavirus/
Yes, an IPF/CC Phase 2 in the US is a good idea. Non dilutive funding for Cancer tumor treatments is possible too for Ifenprodil.
Yes, I think alot of interest will be seen with the Micro dose DMT Clinical Trial approval from UK MHRA.
Everywhere I play there are no redo hands. Bet on the next hand or leave the table...
...GLTA...
Someone has made a claimed smart move and expressed their opinions, so it can now move on, or wait and chase or bragg how smart and right it's been, or poot themself IF getting UK-MHRA approvals (or other pending news) jumps this speculative investment and it then makes A Big Splash entering the NASDAQ. JMHFO...GLTA...
very confusing post.?.
MMND and CMPS are both doing Trials for the mental health uses of psychedelics. CMPS's recent trial was single large dose. I personally wouldn't support that level of a 'high' for anyone and like another company's MOU much better.
They both had larger MCs but are still about $300-400M now. Both have $0 revs.
AGN has followed the different path of the neuroplasticity effects of micro dosed DMT.
Seems a Big difference in the MOUs / applications of psychedelics with different patient groups.
Dr Nutt has significant insights for Both, IMO.
An occasional small dose of Shrooms DOES mitigate some of the side effects of chemo and mental stress, IMO. True hallucinogenic experiences should be left to the young and dumb, IMO...GLTA...
CMPS does depression disorders while AGN is testing neuroplasticity related to Stroke. Dr Nutt would seem to be able to advise both companies about DMT without issues, IMO. He IS one of the most respected voices in this field.
IF AGN finally gets positive news about their UKMHRA clinical trials' applications it may still make that conference, AS the STAR.
BTW, I agree that there are positive effects from 'shrooms for depression and ptsd. Might even help cure cancer.
...GLTA...
Good points about setting up the domain.
Cut & paste the 2nd and 3rd paragraphs to < 200 words and send in the suggestions. You're obviously savvy about that stuff as we see here in posts.
Please...
We all can hope that things are handled better than some past issues. A GOOD SPLASH entering the NASDAQ is Important.!.
I think many folks are holding their cards to see what happens. LM-major-smoki-GVX-Kev-LS5-Ubuck-shell-folks on other MBs-you-me-etc.
Speculation. Your interest seems to imply you still have an investment (or agenda).
...GLTA...
Move to Nasdaq apparently set.
Price is apparently set and CR done. Long Longs get a bend over plan. I had hope for better. Shit hand is almost full while wish hand almost bare for long time investors/supporters.
Sure would have liked to see more positive announcements like this before this CR.
A nice string of PRs with successes would be nice over the next month(s) to help make a significant splash IPO, would be nice... We're sorta stuck again and need new/old investors to be attracted again.
Should happen, IMO...GLTA...
https://finance.yahoo.com/news/algernon-pharmaceuticals-announces-lead-chronic-110000973.html
I think there are possible large increases in demand for RNG/LNG. Battery tech is still for cars mainly, with China having 60% of world graphite supplies. Russian sanctions,?.
...GLTA...
https://finance.yahoo.com/news/australia-png-lng-producers-stand-061606740.html?.tsrc=fin-srch
“With 91% of Americans supporting either medical or recreational cannabis legalization, it’s time for the federal government to respect the will of our voters – both Democrat and Republican alike – and begin a serious conversation about what a post-prohibition America should look like,” said Joyce. “The PREPARE Act will give my colleagues the answers they need to effectively engage on cannabis reform.”
So, you're not invested here anymore and are a supporter of ANY competition. Just kibitzing here. Fine.
Strange to post continuously on MBs for stocks after claiming to not have 'skin in the game', just involved through compassionate concern for real investors.?. Thanks...
...GLTA...
Time stamp.
'Read everything before saying anything'.?.
COVID tests at 90% are fine but for 'enforcement' it is unacceptable, IMHFO...
BLO is presenting new design/product. HANDHELD.
NOT A suitcase interface, for a basic swab (EUA) COVID specific product. As elsewhere COVID IS OVER. Future plans are fine BUT,.. ..
I'll watch the presentation from BLO and then decide.
...GLTA...
There is an IR investor link on the pny1000 web site. They will probably take your money. Ihub will probably allow a new message board to discuss that company. By, GLTY.
I think the UK MHRA will post any news on this site. IDK for sure butt watching (all the time, LOL) for an early opportunity. Posting there might be delayed.?.
https://www.isrctn.com/
...GLTA...
I saw this and thought about the medical angle of BTH as compared to the THC angle of BLO.
The tech has moved forward in some specific areas with good commercial value. I hope to soon see a snazzy high tech sparkly gadget that can be SOLD, here...
Some of my '18-19 profits went to BTH. FAIMS may not be the answer now but back then I always liked their full medical uses concept .
There's lots of talk about 'enforcement' in the pot bill now in US lawmaker's consideration...GLTA...
https://www.cnet.com/health/fda-authorizes-breath-test-for-covid-19-diagnosis/?msclkid=794d2d5dbc5811ecbe79434d376c7f79
The technology of the PNY-1000 instrument is a portable system for gas chromatography (GC) coupled
with a quadrupole mass spectrometer (MS). The linear quadrupole is specifically designed to function as
a GC detector. The analysis of unknown VOC mixtures is performed to identify specific VOC compounds
at a high resolution to detect active SARS-CoV-2 infections.
The InspectIR COVID-19 Breathalyzer test for use on the PNY-1000 instrument is designed to detect Five
VOCs from the ketone and aldehyde families associated with SARS-CoV-2 (COVID-19) viral infection from
exhaled breath samples
https://www.fda.gov/media/157723/download?msclkid=2f6f5d15bc5b11ec89806ee6fde6cd4e
AGN's Microdose / sub hallucinogenic DMT pre clinical work completed by Charles River Labs.
UK MHRA clinical trial applications filed Jan 2022
GMT DMT produced.
Hammerschmidt to run the Phase 1 CT and experts hired for planning and participation in Phase 2 ...
5 year timeline for the Ninion's, R+D and pre clinical work...
https://ir.algernonpharmaceuticals.com/news-events/press-releases/detail/5/algernon-pharmaceuticals-completes-manufacturing-of
"Anthony Rudd, MB, BChir, FRCP, CBE is an emeritus professor of Stroke Medicine at Kings College London and recently retired as a consultant stroke physician at Guy’s and St Thomas’ Hospital. He was the London Stroke Clinical Director from 2010-2019 and the National Clinical Director for Stroke for NHS England from 2013-2019, where he oversaw dramatic improvements in the paradigm of NHS stroke treatment."
"Dr. Robert Simister
Robert Simister MA MB BS PhD FRCP is a consultant neurologist and stroke physician as well as an honorary senior lecturer at University College London, where he also serves as the Clinical Lead for the Comprehensive Stroke Service and the Clinical Director of Stroke Medicine and Acute Neurology. Since 2019, he has been the Joint Clinical Director for the London Stroke Clinical Network."
https://ir.algernonpharmaceuticals.com/news-events/press-releases/detail/10/algernon-announces-positive-feedback-on-its-planned-phase
...GLTA...
Almost No one posts here anymore. sadly true.
AGN's management,and their employees are doing the hard jobs attempting to produce 'stellar' results as a speculative pharma with the repurposed drug concept.
ON A MINIMAL Budget.
This is a Home Run or bust play for most as any speculative investment should be considered, IMO. (Some Trading at major events of course)
AGN has attracted Dr Strassman and other top names and medical institutions like Charles River Lab's and Hammerschmidt's involvement in the micro-dose / sub hallucinogenic use of DMT for the treatments of Strokes. The IP has been licensed and MOAs filed.
Dr. North is the consultant for the IP and MOAs involved with the Ifenprodil SCLC / Pancreatic Cancer Tumor treatments that has so far received support from the FDA.
Apparently, the trending from the IPF/CC clinical trial down under was strong enough to pursue full strength Cronic Cough clinical Trials.
AGN has again dug into the NASH re-purposed drug bag from Dr Mark Williams (merger) and is now pursuing CKD treatments. Dr Williams is on the BOD now.
I am holding AGN stock and may buy more depending on the winds. Cant see any reason to sell, especially now at this bottom created by the 'not stelar enough' results from our COVID trial, vaccines, BP and the share consolidation. Ouch,,, but there are new cards in play,,, with an IPO carrot,,, possibilities of a NASDAQ listing with success from any of the three THREE three paths. Financing at >$30+.?.$50.?.
I SEE THREE When/IF...?...GLTA...
This is SPECTOWN . .. My money, My responsibilities... GLTA...